Anaphylaxis and COVID-19 vaccines
Copyright © 2021 Elsevier Masson SAS. All rights reserved..
Vaccines against COVID-19 are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have rapidly been reported after SARS-CoV2 RNA vaccines. This risk is now measured at 2.5-11/1,000,000 in the context of vaccine safety surveillance programs and only one case was documented to be due to polyethylene glycol. Suggestions for its role are indirect. The COVID-19 vaccination is rolling out vastly and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. It is important to restore confidence about vaccination with COVID-19 mRNA and other vaccines and current data confirm their safety with no greater mortality than previous vaccines. Anaphylaxis is a complication that should be recognized immediately, be treated with epinephrine and which is not limiting and allows re-vaccination of some patients with pre-medication. It is important to recognize populations at risk such as women, patients with a history of allergies and anaphylaxis and to recognize the rare patients who have mast cell activating diseases. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care, highlighting the key role of allergists in the vaccination programmes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Revue francaise d'allergologie (2009) - 61(2021), 8 vom: 01. Dez., Seite 8S30-8S35 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
L'anaphylaxie et les vaccins COVID-19 |
|---|
| Beteiligte Personen: |
Castells, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse reaction |
|---|
| Anmerkungen: |
Date Revised 21.12.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/S1877-0320(21)00439-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335164048 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335164048 | ||
| 003 | DE-627 | ||
| 005 | 20231225225234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/S1877-0320(21)00439-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335164048 | ||
| 035 | |a (NLM)34980951 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Castells, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anaphylaxis and COVID-19 vaccines |
| 246 | 3 | 3 | |a L'anaphylaxie et les vaccins COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Vaccines against COVID-19 are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have rapidly been reported after SARS-CoV2 RNA vaccines. This risk is now measured at 2.5-11/1,000,000 in the context of vaccine safety surveillance programs and only one case was documented to be due to polyethylene glycol. Suggestions for its role are indirect. The COVID-19 vaccination is rolling out vastly and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. It is important to restore confidence about vaccination with COVID-19 mRNA and other vaccines and current data confirm their safety with no greater mortality than previous vaccines. Anaphylaxis is a complication that should be recognized immediately, be treated with epinephrine and which is not limiting and allows re-vaccination of some patients with pre-medication. It is important to recognize populations at risk such as women, patients with a history of allergies and anaphylaxis and to recognize the rare patients who have mast cell activating diseases. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care, highlighting the key role of allergists in the vaccination programmes | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adverse reaction | |
| 650 | 4 | |a Allergy | |
| 650 | 4 | |a Anaphylaxis | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Polyethylene-glycol | |
| 650 | 4 | |a SARS-COVID vaccine | |
| 650 | 4 | |a Vaccine | |
| 700 | 1 | |a Demoly, P |e verfasserin |4 aut | |
| 700 | 1 | |a Tanno, L K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue francaise d'allergologie (2009) |d 2009 |g 61(2021), 8 vom: 01. Dez., Seite 8S30-8S35 |w (DE-627)NLM272947334 |x 1877-0312 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2021 |g number:8 |g day:01 |g month:12 |g pages:8S30-8S35 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1877-0320(21)00439-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2021 |e 8 |b 01 |c 12 |h 8S30-8S35 | ||